| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.041 | 0.4 |
| mRNA | PD-0332991 | CCLE | pan-cancer | AAC | 0.042 | 0.4 |
| mRNA | lapatinib | CCLE | pan-cancer | AAC | 0.025 | 0.6 |
| mRNA | LBW242 | CCLE | pan-cancer | AAC | -0.00099 | 1 |
| mRNA | ML239 | CTRPv2 | pan-cancer | AAC | 0.33 | 1e-18 |
| mRNA | ruxolitinib | CTRPv2 | pan-cancer | AAC | 0.28 | 3e-15 |
| mRNA | decitabine | CTRPv2 | pan-cancer | AAC | 0.2 | 3e-12 |
| mRNA | nelarabine | CTRPv2 | pan-cancer | AAC | 0.27 | 6e-11 |
| mRNA | AZD1480 | CTRPv2 | pan-cancer | AAC | 0.32 | 4e-09 |
| mRNA | decitabine:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.19 | 8e-09 |